CompletedPhase 4

N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection

Spain46 participantsStarted 2003-01

Plain-language summary

Study hypothesis: N-acetylcysteine (NAC) can reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Hepatectomy Exclusion Criteria: * ASA 4 * Cirrhosis * Creatinine \> 1.2 mg/dL * Associate surgery (pancreatic or splenectomy) * Intraoperative bleeding \> 2 L. * Active infection of inflammatory disease

What they're measuring

Laboratory results

Timeframe: 24 hours

Trial details

NCT IDNCT01223326

SponsorClinica Universidad de Navarra, Universidad de Navarra

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-10

View on ClinicalTrials.gov More Hepatectomy trials